TI-GI CMV disease was defined as an evidence of CMV infection either from (1) typical CMV cytopathic change demonstrated on hematoxylin and eosin (H&E) staining or (2) positive staining for CMV antigen by immunohistochemistry (IHC) in the tissue specimens from gastrointestinal tract (i.e., esophagus, stomach, small intestine, and colon), in which the specimens were obtained from surgical resection or gastrointestinal endoscopy with biopsy. All tissue histology specimens were reviewed by single clinical pathologist (P.W.) who was blinded to clinical characteristics of the patients to confirm the diagnosis of TI-GI CMV before including the patients into the analysis.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.